Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBCBS South Carolina specialty drug Coverage & Prio…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Drug coverage criteria for specialty/immunology medications (partial list)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document section lists products and their coverage criteria (indications, required medical information, prescriber restrictions, coverage duration, and other criteria) affecting Blue Cross Blue Shield - South Carolina members for the named specialty medications in the immunology/rheumatology area. It applies to benefits and providers seeking prior authorization for these products.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug coverage criteria for specialty/immunology medications (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Last ReviewNov 3, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required prior therapy documentation, and specialist consultation when specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20products listed in this excerpt
    12 monthsmost common coverage duration
    6 monthsinitial duration (selected)
    ID 25384formulary identifier

    Coverage Criteria (Initial and Continuation)

    Actimmune — Initial/Continuation

    Covered when ALL of the following are met

    Indication: Diagnosis of chronic granulomatous disease (CGD) OR severe malignant osteopetrosis (SMO)

    Coverage duration 12 months; approve continuation of prior therapy

    Adalimumab biosimilars and originator — Indication-specific criteria

    Covered when ALL of the following per indication are met

    RA (initial): Diagnosis of moderately to severely active rheumatoid arthritis AND minimum 3-month trial and failure, contraindication, or intolerance (TF/C/I) to one conventional therapy at maximally tolerated doses (methotrexate, leflunomide, or sulfasalazine)3 months

    Prescribed by or in consultation with a rheumatologist; initial duration often 6 months; reauth 12 months

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug coverage criteria for specialty/immunology medications (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Last ReviewNov 3, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required prior therapy documentation, and specialist consultation when specified.
    SourceLink
    On This Page
    Coverage Criteria (Initial and Continuation)Formulary Identifiers and Billing CodesQuick Reference: Key Thresholds & Age LimitsPrior Authorization, Documentation & Step TherapyPolicy Background and ScopeDefinitions and Key Terms
    PJIA (initial): Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis AND minimum 6-week TF/C/I to methotrexate or leflunomide at maximally tolerated doses6 weeks

    Prescribed by or in consultation with a rheumatologist

    Psoriasis (initial): Diagnosis of moderate to severe chronic plaque psoriasis AND one of: >=3% BSA involvement, severe scalp, OR palmoplantar/facial/genital involvement AND minimum 4‑week TF/C/I to topical therapies (eg, corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors)4 weeks

    Prescribed by or in consultation with a dermatologist; initial duration commonly 6 months; reauth 12 months

    Ankylosing spondylitis (initial): Diagnosis of active ankylosing spondylitis AND minimum 1‑month TF/C/I to a NSAID at maximally tolerated doses1 month

    Prescribed by or in consultation with a rheumatologist; reauth requires improvement in disease activity metrics

    Crohn's disease (initial): Diagnosis of moderately to severely active Crohn's disease AND one of: frequent diarrhea and abdominal pain, >=10% weight loss, complications (eg, obstruction, fever, abdominal mass), abnormal labs (eg, CRP), OR CDAI >220CDAI > 220 optional

    Prescribed by or in consultation with a gastroenterologist; initial typically 6 months; reauth requires evidence of mucosal healing or lab improvement

    Adbry — Atopic dermatitis

    Covered when ALL of the following are met

    Atopic dermatitis (initial): Diagnosis of moderate to severe atopic dermatitis AND either >=10% BSA involvement OR SCORAD >=25 AND trial and failure/contraindication/intolerance to at least two topical agents (medium+ potency topical corticosteroid, pimecrolimus, tacrolimus, or crisaborole)>=10% BSA or SCORAD>=25; 30-day trial

    Initial age ≥12 years; prescribed by or in consultation with dermatologist or allergist/immunologist; initial 6 months, reauth 12 months with evidence of response

    Pulmonary arterial hypertension — general criteria

    Covered when ALL of the following are met

    PAH (initial): Diagnosis of pulmonary arterial hypertension (PAH) AND symptomatic disease AND either hemodynamic confirmation by right heart catheterization OR current use of any therapy for PAH

    Prescribed by or in consultation with pulmonologist or cardiologist; initial duration 6 months; reauth 12 months with documented positive response

    Everolimus — oncology/TSC

    Covered when ALL of the following are met

    Everolimus indications: SEGA associated with TSC requiring therapeutic intervention; advanced RCC after trial/failure of sunitinib or sorafenib; progressive unresectable/metastatic pNET; renal angiomyolipoma with TSC; HR+ HER2‑ advanced breast cancer after letrozole/anastrozole failure; progressive well-differentiated non-functional NET of GI or lung origin unresectable locally advanced or metastaticage >=1 year for SEGA

    Coverage 12 months; approve continuation of prior therapy

    Prolastin-c — AAT deficiency

    Covered when ALL of the following are met

    AAT deficiency (initial): Diagnosis of congenital alpha‑1 antitrypsin deficiency with emphysema AND continued conventional treatment for emphysema AND one of: homozygous PiZZ/PiZ(null)/Pi(null)(null) phenotypes OR other rare genotypes associated with pre‑treatment serum AAT <11 µM/L (or equivalent mg/dL thresholds)pre‑treatment serum AAT <11 µM/L (or equivalent)

    Coverage 12 months; reauth requires positive clinical response

    Dalfampridine — Walking improvement in MS

    Covered when ALL of the following are met

    MS walking impairment (initial): Diagnosis of multiple sclerosis with physician confirmation of difficulty walking (e.g., timed 25‑foot walk) AND EDSS ≤7 OR not restricted to wheelchair if EDSS not measuredEDSS <=7

    Prescribed by or in consultation with neurologist; initial 6 months, reauth 12 months with improvement in walking

    COPD (maintenance)

    Covered when ALL of the following are met

    COPD maintenance: Diagnosis of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema for maintenance treatment of bronchoconstriction

    Coverage duration 12 months; subject to Part B vs Part D review

    Arikayce — MAC lung disease (refractory)

    Covered when ALL of the following are met

    Arikayce for MAC lung disease: Diagnosis of Mycobacterium avium complex (MAC) lung disease AND used as part of combination antibacterial regimen AND patient did not achieve at least two negative sputum cultures after ≥6 months of multidrug background regimen

    Prescribed by or in consultation with infectious disease specialist or pulmonologist; coverage 12 months

    Teriflunomide — MS

    Covered when ALL of the following are met

    MS initial: Diagnosis of a relapsing form of multiple sclerosis

    Not used in combination with another disease‑modifying therapy; prescribed by or in consultation with neurologist; coverage 12 months

    Augtyro — ROS1 or NTRK-positive tumors

    Covered when ANY of the following indications are met

    NSCLC (ROS1): Diagnosis of locally advanced or metastatic NSCLC with ROS1 rearrangement

    Coverage 12 months

    Solid tumors (NTRK): Diagnosis of unresectable, locally advanced, or metastatic solid tumor with NTRK gene fusion AND disease progressed following prior treatment OR no satisfactory alternative treatments

    Coverage 12 months

    Austedo — Chorea and TD

    Covered when ANY of the following are met

    Huntington's chorea: Diagnosis of chorea associated with Huntington's disease

    Prescribed by or in consultation with a neurologist; coverage 12 months

    Tardive dyskinesia: Diagnosis of tardive dyskinesia AND persistent symptoms despite trial of dose reduction/taper/discontinuation of offending medication OR patient not candidate for such trial

    Prescribed by or in consultation with neurologist or psychiatrist; initial 3 months, reauth 12 months

    Avmapki Fakzynja — LGSOC with KRAS mutation

    Covered when ALL of the following are met

    LGSOC KRAS‑mutant: Diagnosis of recurrent low‑grade serous ovarian cancer AND presence of KRAS mutation by FDA‑approved or CLIA test AND prior systemic therapy

    Coverage 12 months; approve continuation of prior therapy

    Ayvakit — GIST and Mastocytosis

    Covered when ANY of the following indications are met

    GIST PDGFRA exon 18: Diagnosis of unresectable or metastatic GIST with PDGFRA exon 18 mutation (including D842V)

    Coverage 12 months

    Advanced Systemic Mastocytosis: Diagnosis of AdvSM (ASM, SM‑AHN, or MCL) with platelet count >50 x10^9/Lplatelet count >50 x10^9/L

    Coverage 12 months

    Indolent Systemic Mastocytosis: Diagnosis of ISM with platelet count >50 x10^9/Lplatelet count >50 x10^9/L

    Coverage 12 months

    Balversa — FGFR3-altered UC

    Covered when ALL of the following are met

    UC with FGFR3 alteration: Diagnosis of locally advanced or metastatic urothelial carcinoma AND presence of susceptible FGFR3 genetic alteration by FDA‑approved or CLIA test AND disease progressed after ≥1 prior systemic therapy

    Prior PD‑1/PD‑L1 therapy history or not candidate for such therapy; coverage 12 months

    Benlysta — SLE and Lupus Nephritis

    Covered when ALL of the following are met

    SLE initial: Diagnosis of active systemic lupus erythematosus AND autoantibody positive (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL) AND currently receiving at least one standard‑of‑care treatment

    Prescribed by or in consultation with a rheumatologist; age ≥5 years for IV/SC; coverage 6 months initial/reauth

    Lupus nephritis initial: Diagnosis of active lupus nephritis AND currently receiving standard‑of‑care treatment (e.g., corticosteroids with mycophenolate or cyclophosphamide)

    Prescribed by or in consultation with nephrologist or rheumatologist; age ≥5 years; coverage 6 months

    Besremi — Polycythemia Vera

    Covered when ANY of the following diagnostic pathways are met

    PV diagnostic pathways: Diagnosis of polycythemia vera confirmed by hematologic criteria and bone marrow findings plus JAK2 mutation or subnormal erythropoietin OR sustained absolute erythrocytosis with JAK2 mutation and subnormal erythropoietin

    For high‑risk PV only; coverage 12 months; approve continuation of prior therapy

    Bosulif — Ph+ CML

    Covered when ALL of the following are met

    Ph+ CML: Diagnosis of Philadelphia chromosome‑positive chronic myelogenous/myeloid leukemia

    Coverage 12 months; continuation of prior therapy approved

    Braftovi — BRAF V600 indications

    Covered when ANY of the following are met

    Melanoma BRAF V600E/K: Unresectable or metastatic melanoma with BRAF V600E or V600K mutation detected by FDA‑approved or CLIA test AND used in combination with Mektovi

    Coverage 12 months

    Colorectal cancer BRAF V600E: Unresectable/advanced or metastatic colorectal cancer with BRAF V600E mutation AND used in combination with cetuximab or mFOLFOX6 per regimen

    Coverage 12 months

    NSCLC BRAF V600E: Metastatic NSCLC with BRAF V600E mutation detected by FDA‑approved or CLIA test

    Coverage 12 months

    Briviact — Seizures

    Covered when ALL of the following are met

    Partial‑onset seizures: Diagnosis of partial‑onset seizures

    Patient age ≥1 month; coverage 12 months; approve continuation of prior therapy

    Brukinsa — MCL, CLL/SLL, WM, MZL, FL

    Covered when ANY of the following hematologic malignancy indications are met

    Mantle cell lymphoma: Diagnosis of MCL with at least one prior therapy OR treatment‑naive ineligible for HSCT when used in combination with bendamustine+rituximab

    Coverage 12 months; continuation of prior therapy approved

    Exenatide — Type 2 Diabetes

    Covered when ANY of the following are met

    T2DM initial: Diagnosis of type 2 diabetes mellitus with supporting medical records OR laboratory evidence (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour OGTT ≥200 mg/dL)

    Coverage 12 months; reauth requires positive clinical response

    Cablivi — aTTP

    Covered when ALL of the following are met

    aTTP: Diagnosis of acquired thrombotic thrombocytopenic purpura; first dose administered by healthcare provider IV bolus; used with immunosuppressive therapy AND either with plasma exchange OR within 59 days after last plasma exchange

    Prescribed by or in consultation with hematologist/oncologist; coverage 3 months

    Cabometyx — Solid tumors

    Covered when ANY of the following solid tumor indications are met

    RCC/HCC/DTC: Indications include renal cell carcinoma, hepatocellular carcinoma (trial/failure to Nexavar), differentiated thyroid cancer progressed after VEGFR‑targeted therapy; selected neuroendocrine tumors

    Coverage 12 months; some age‑specific criteria (DTC ≥12 years); continuation approved

    Calquence — MCL, CLL/SLL

    Covered when ANY of the following are met

    MCL/CLL (indications): Diagnosis of mantle cell lymphoma with specified criteria OR chronic lymphocytic leukemia/small lymphocytic lymphoma per labeling

    Coverage 12 months; continuation approved

    Teriflunomide is covered for members with a relapsing form of multiple sclerosis when prescribed by or in consultation with a neurologist and all other product-specific criteria are met. Coverage is limited to monotherapy: Teriflunomide must not be used in combination with another disease-modifying therapy for MS. Initial and reauthorization approvals are generally for 12 months, and reauthorization requires documentation of a positive clinical response to therapy.

    Formulary Identifiers and Billing Codes

    Formulary identifiersmixed
    Formulary ID: 25384Formulary identifier referenced across listed products
    Cosentyx productsmixedCovered
    Cosentyx INJ 150MG/MLProduct listed (secukinumab) 150 mg/mL
    Cosentyx INJ 125MG/5MLProduct listed (secukinumab) 125 mg/5 mL
    Cosentyx Sensoready PenCosentyx Sensoready Pen formulation
    Cosentyx UnoreadyCosentyx Unoready formulation
    CinryzemixedCovered
    CinryzeC1-INH concentrate for prophylaxis of hereditary angioedema
    DeferasiroxmixedCovered
    DeferasiroxOral iron chelator (Exjade/Other)
    PyrimethaminemixedCovered
    Pyrimethamine TABSPyrimethamine tablets
    Formulary identifiermixed
    Formulary ID: 25384Formulary identifier repeated for listed products
    No explicit billing or diagnosis codes listed in this segmentmixed
    No codes listed
    Formulary identifiersmixed
    Formulary ID: 25384Formulary identifier for listed products (version 18)
    No explicit billing or diagnosis codes provided in these chunksmixed
    No codes listed
    Products listedmixed
    No codes listed
    Formulary Referencemixed
    Formulary ID: 25384Formulary reference for listed products
    Formulary identifiermixed
    Formulary ID: 25384Formulary identifier for listed products
    Orencia product listingsmixed
    Orencia INJ 250MGProduct name / strength as listed
    Orencia INJ 125MG/MLProduct name / strength as listed
    Orencia ClickjectProduct name / device as listed
    PAH therapiesmixed
    OpsumitMacitentan (PAH agent) product listing
    OrenitramTreprostinil oral (PAH) and titration kits
    Metabolic / diabetes productmixed
    OzempicSemaglutide product listing
    Lipid-lowering therapymixed
    PraluentAlirocumab product listing
    Products listedmixed
    N/AProduct lists (no procedural codes provided in these chunks)
    No explicit codes in excerptmixed
    No codes listed
    Formulary identifiersmixed
    Formulary ID: 25384Formulary identifier referenced for multiple products in this excerpt
    Formulary identifiersmixed
    Formulary ID: 25384Referenced formulary identifier for entries in this section

    Quick Reference: Key Thresholds & Age Limits

    inv-161: Topical therapy trial duration for PsO
    Required trial durationMinimum 4-week trial of topical therapies for plaque psoriasis prior to biologic approval
    ContextApplies to plaque psoriasis initial criteria (>=3% BSA or severe scalp/palmoplantar/facial/genital involvement)
    Evidence requiredDocumentation of trial/failure, contraindication, or intolerance (TF/C/I) to topical agents (eg, corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors)
    inv-162: RA conventional therapy trial duration
    Required trial durationMinimum 3-month trial and failure/contraindication/intolerance to one conventional DMARD (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses
    Applies toRheumatoid arthritis initial therapy prior to biologic/JAK therapy
    PrescriberPrescribed by or in consultation with a rheumatologist as specified
    inv-163: PJIA conventional therapy trial duration
    Required trial durationMinimum 6-week trial and failure/contraindication/intolerance to methotrexate or leflunomide at maximally tolerated doses
    Applies toPolyarticular juvenile idiopathic arthritis (PJIA) initial therapy prior to biologic approval
    PrescriberPrescribed by or in consultation with a rheumatologist
    inv-164: Atopic dermatitis severity thresholds
    Severity thresholdAtopic dermatitis defined as >=10% body surface area involvement OR SCORAD >=25
    Prior topical therapyTrial and failure/contraindication/intolerance to at least two topical agents (30-day supply; 14-day for topical corticosteroids)
    Age minimumInitial: patient is 12 years of age or older
    inv-170: Age minimum for CF indication
    Age minimumPatient must be 7 years of age or older for indicated cystic fibrosis therapy
    ContextApplies to CF products requiring evidence of Pseudomonas aeruginosa in the lungs
    Coverage durationInitial and reauthorization: 12 months
    inv-176: Peripheral blood eosinophils
    Peripheral blood eosinophils>= 150 cells/µL (baseline) as policy definition of eosinophilic phenotype for asthma-related indications
    Alternate threshold>= 300 cells/µL within past 12 months noted for some criteria
    ApplicationUsed to determine eligibility for anti-eosinophil biologics (eg, dupilumab, mepolizumab, benralizumab, Fasenra) per indication-specific rules
    inv-192: LDL thresholds on therapy
    LDL thresholds on therapyLDL ≥55 mg/dL with ASCVD or LDL ≥70 mg/dL without ASCVD; or requirement of ≥25% LDL-C reduction to achieve goal (lab within last 120 days while on maximally tolerated regimen)
    DocumentationRecent LDL value while on maximal tolerated lipid-lowering therapy required within specified timeframe
    Coverage timingInitial approvals commonly 6 months; reauthorization 12 months
    inv-198: Age restriction example (HeFH/HoFH)
    Age restriction exampleHeFH/HoFH initial: patient age 10 years or older
    ContextApplies to PCSK9 inhibitor eligibility (HeFH/HoFH) per policy entries
    Initial/reauth durationsInitial commonly 6 months; reauth 12 months
    inv-206: Parathyroid hormone lifetime duration
    Lifetime duration limitTotal lifetime treatment with parathyroid hormone analogs (eg, teriparatide) must not exceed 24 months
    Initial coverageInitial authorization documented as 24 months where applicable
    ReauthorizationReauth allowed only if lifetime limit not exceeded and continued high fracture risk or other criteria documented

    Prior Authorization, Documentation & Step Therapy

    Prior Authorization

    Prior authorization required

    Prior authorization is required for these products; submissions must include the patient diagnosis, documentation of required prior therapy trials (or contraindication/intolerance), prescriber specialty or consultation when specified, and the requested coverage duration (initial vs reauthorization).

    • Include diagnosis matching the product-specific criteria.
    • Provide evidence of required prior trials, failures, contraindication, or intolerance (TF/C/I) with duration when specified.
    • Indicate prescriber specialty or consultation when the product requires it.
    Prior Authorization

    Prior authorization required (product list)

    Prior authorization is required for the listed formulary products in chunks 18–37; approval typically requires the indication-specific documentation noted in each product entry and most approvals are for 12 months.

    • Submit indication-specific documentation per product (diagnostic tests, labs, prior therapy history).
    • Expect common approval duration of 12 months unless a product-specific shorter initial period is specified.
    Prior Authorization

    Cosentyx products — prior authorization

    Cosentyx (secukinumab) requires prior authorization with disease-specific diagnostic documentation and evidence of required prior therapy trials; initial approvals are commonly limited to 6 months with reauthorization requiring evidence of clinical response.

    • Provide diagnosis and disease-specific measures (e.g., BSA for psoriasis, objective inflammation for axial disease).
    • Document trial and failure/contraindication/intolerance to required topical/systemic or NSAID therapies as applicable.
    • Prescriber should be the specialist or consult (dermatologist, rheumatologist) as listed.
    Prior Authorization

    Cinryze — prior authorization

    Cinryze prior authorization is required for HAE prophylaxis and must include confirmation of HAE by low C1‑INH antigenic or functional level; concomitant prophylactic HAE treatments are not permitted.

    • Submit documentation of C1‑INH antigenic level below normal OR C1‑INH functional level below normal.
    • Do not request combination prophylactic HAE treatments—policy excludes combination use.
    Prior Authorization

    Dupilumab prior authorization

    Dupilumab requires prior authorization with indication‑specific documentation (e.g., eosinophil thresholds for eosinophilic asthma, eos/hpf for EoE) and evidence of prior controller therapy or specified trials per indication.

    • For eosinophilic asthma: baseline blood eosinophils ≥150 cells/µL and prior controller therapy per age band.
    • For EoE: ≥15 intraepithelial eosinophils per high‑power field and exclusion of other causes; prior PPI or topical steroid trial.
    Prior Authorization

    Enbrel prior authorization

    Enbrel prior authorization is required for its rheumatologic and dermatologic indications and must document the diagnosis and required prior conventional DMARD trial (typically a 3‑month trial for RA) and prescriber specialty involvement.

    • Provide diagnosis of the specific indication (RA, PJIA, PsO, etc.).
    • Document minimum required conventional therapy trial duration (e.g., 3 months for RA; 6 weeks for PJIA; 4 weeks topical trial for PsO).
    • Prescriber: rheumatologist or appropriate specialist or consultation.
    Prior Authorization

    Fasenra PA criteria

    Fasenra prior authorization requires documentation of severe eosinophilic asthma criteria: baseline peripheral blood eosinophils ≥150 cells/µL, history of exacerbations or hospitalization in the past 12 months, and required prior controller therapy trials matched to age groups; reauthorization requires evidence of clinical response.

    • Document baseline eosinophils ≥150 cells/µL.
    • Provide history of ≥2 exacerbations requiring systemic corticosteroids or prior asthma‑related hospitalization in past 12 months.
    • Show trials of required inhaled corticosteroid/controller regimens (age‑specific).
    Prior Authorization

    ALK-targeted therapy PA criteria

    ALK‑targeted therapies (example: lorlatinib) require prior authorization with documentation of ALK rearrangement by an FDA‑approved or CLIA‑approved test and that the patient is ALK‑inhibitor naïve for initial approval.

    • Provide molecular test result confirming ALK rearrangement (FDA‑approved or CLIA test).
    • Confirm patient has not previously received an ALK inhibitor for initial approval.
    Prior Authorization

    Prior authorization required (general)

    Prior authorization is required generally across the formulary; requests must include the listed diagnosis, product‑specific required prior trials/durations, prescriber specialty when specified, and evidence of response for reauthorization.

    • Attach clinical records documenting diagnosis and prior therapy history.
    • Indicate initial versus reauthorization and include requested duration.
    • For reauthorization, provide objective evidence of clinical benefit per product criteria.
    Prior Authorization

    LEMS prior auth

    LEMS initial therapy requires prior authorization documenting the diagnosis of LEMS, patient age ≥6 years, and that the medication is prescribed by or in consultation with a neurologist; coverage duration is 12 months with reauthorization contingent on positive clinical response.

    • Submit documentation confirming LEMS diagnosis.
    • Confirm patient is ≥6 years of age.
    • Include neurologist involvement or consultation notes for the request.
    Prior Authorization

    Prior authorization and duration

    Prior authorization submissions must include the diagnosis, required product‑specific documentation and history, and will commonly indicate coverage duration (initial and reauthorization timeframes are listed per product entries).

    • Most products list initial durations (often 6 months) and reauthorization durations (commonly 12 months).
    • Ensure charts show baseline metrics and planned monitoring to support the requested duration.
    Prior Authorization

    Prior authorization requirement

    Prior authorization is required per formulary entries; approvals commonly require documentation of diagnosis and prior therapy failure/intolerance/contraindication where specified.

    • Follow the product‑specific required medical information fields when preparing the PA submission.
    • When a prior therapy trial is required, include dates, doses, and reason for failure or intolerance.
    Prior Authorization

    Prior authorization required (molecular testing)

    Prior authorization is required and, when applicable, must include required molecular testing results, prior therapy history, and prescriber/specialist documentation as listed per product.

    • Attach FDA‑approved or CLIA‑certified molecular test reports when molecularly targeted agents are requested.
    • Include specialist consultation notes when the product requires a specialist prescriber.
    Prior Authorization

    Prior authorization requirement

    Prior authorization is required with documentation of the listed diagnosis and disease‑specific criteria; coverage durations and any prescriber restrictions apply per drug entry.

    • Provide disease‑specific labs, imaging or scores as required (e.g., BSA for psoriasis, CDAI for Crohn's).
    • Confirm prescriber specialty or consultation if the entry requires it.
    Prior Authorization

    Orencia prior authorization

    Orencia prior authorization requires documentation of the diagnosis (RA, PJIA, PsA) and a prior trial/failure or intolerance to specified conventional DMARDs (minimum 3 months for RA; 6 weeks for PJIA); prescriber specialty is required.

    • Include documentation of TF/C/I to methotrexate, leflunomide, or sulfasalazine as applicable.
    • Prescriber should be a rheumatologist or involve rheumatology consultation.
    Prior Authorization

    Praluent prior authorization

    Praluent prior authorization requires documented diagnosis (HeFH, ASCVD, primary HLD, or HoFH), evidence of maximally tolerated statin therapy or documented statin intolerance, recent LDL values on therapy meeting policy thresholds, and genetic confirmation for HoFH when applicable.

    • Attach LDL labs within the required timeframe (e.g., within 120 days) showing the threshold criteria.
    • Document statin tolerance history or contraindication; for HoFH include genetic confirmation or specified LDL/xanthoma family history.
    Prior Authorization

    PAH therapies prior authorization

    PAH therapies require prior authorization documenting symptomatic PAH confirmed by right heart catheterization or that the patient is currently on PAH therapy; initial prescribing should be by or in consultation with a pulmonologist or cardiologist.

    • Provide right heart catheterization report or documentation that the patient is currently receiving PAH therapy.
    • Include pulmonology or cardiology prescriber or consultation notes.
    Prior Authorization

    PA required for PCSK9 inhibitors

    Prior authorization for PCSK9 inhibitors requires documentation of diagnosis, trial or maximally tolerated lipid‑lowering therapy (or statin intolerance), and recent LDL‑C values meeting the policy thresholds; initial approval is commonly 6 months with reauthorization at 12 months.

    • Include LDL labs drawn while on maximally tolerated therapy (within last 120 days).
    • Document statin use or intolerance (attempts with at least two statins when claiming intolerance).
    Prior Authorization

    PA required for eltrombopag

    Eltrombopag prior authorization is required and must document the indication (ITP, SAA, HCV‑associated thrombocytopenia), baseline platelet counts (eg, <30,000/mcL for ITP), and specialist prescribing or consultation where specified.

    • For ITP: include baseline platelet count <30,000/mcL and history of TF/C/I to corticosteroids, IVIG, or splenectomy.
    • For other indications, include the diagnosis‑specific lab thresholds and specialist notes.
    Prior Authorization

    Prior authorization and therapy-failure requirements

    Prior authorization requires evidence of diagnosis and prior therapy trials or failures where specified (for example, TNF inhibitor failure or conventional therapy TF/C/I) and prescriber specialty/consultation when required.

    • Provide clear documentation of prior biologic or conventional therapy trials and clinical rationale for escalation.
    • Attach specialist consult notes when the policy requires specialist involvement.
    Prior Authorization

    Prior authorization required (per product)

    Prior authorization is required per product entries with documentation of diagnosis, required prior therapy trials or laboratory confirmation as specified; typical coverage durations and any prescriber consultation requirements are listed per product.

    • Follow each product's 'Required Medical Information' and 'Other Criteria' fields exactly when preparing the PA.
    • Note initial vs reauthorization duration as specified in the product entry.
    Prior Authorization

    Prior authorization and duration

    Prior authorization submissions should indicate initial vs reauthorization; most oncology and specialty agents list 12‑month coverage durations for reauthorization and require documentation supporting continuation of prior therapy.

    • For oncology/specialty agents, include prior therapy history and objective evidence supporting continuation.
    • Expect reauthorization commonly set to 12 months.
    Prior Authorization

    Parathyroid hormones PA requirements

    Parathyroid hormone products (e.g., teriparatide) require prior authorization documenting BMD/T‑score or fracture history and prior therapy failures; initial coverage is commonly 24 months and lifetime cumulative parathyroid hormone therapy must not exceed 24 months.

    • Provide BMD T‑scores, fracture history, FRAX when applicable, and prior osteoporosis therapy trials.
    • Note lifetime treatment duration limit of 24 months in authorization documentation.
    Step Therapy

    Step therapy / prior medication trials

    Many indications require documented step therapy: trial and failure, contraindication, or intolerance to specified conventional therapies (e.g., 3‑month TF/C/I to methotrexate/leflunomide/sulfasalazine for RA; topical therapy trial for psoriasis).

    • Document dates, doses and reasons for failure/intolerance of prior therapies.
    • Ensure minimum trial durations match the policy thresholds (e.g., 3 months for RA; 4 weeks topical for psoriasis).
    Step Therapy

    Required trials before Caplyta

    Caplyta authorization requires documented trial and failure/contraindication/intolerance to specified oral generic atypical antipsychotics: two agents for schizophrenia or specified agents for bipolar depression.

    • For schizophrenia: document TF/C/I to two listed oral generic atypical antipsychotics.
    • For bipolar depression: document TF/C/I to quetiapine or olanzapine as specified.
    Step Therapy

    Step therapy for psoriasis/axial disease

    For psoriasis and related axial disease indications, prior authorization and approval require trial and failure (or contraindication/intolerance) of specified topical, systemic, or NSAID agents as applicable before biologic approval; specific step requirements vary by product and indication.

    • For plaque psoriasis: document ≥4‑week TF/C/I to topical therapies and BSA involvement per policy.
    • For AS/nr‑axSpA: document NSAID trial(s) of specified duration prior to biologic therapy.
    Step Therapy

    Dupilumab step therapy

    Dupilumab step therapy requires prior use of inhaled corticosteroids plus additional controller therapy or maximized ICS/LABA regimens before approval in many asthma age‑groups; include documentation of controller regimens and exacerbation history.

    • For asthma: show prior controller therapy per age group (e.g., medium/high‑dose ICS plus additional controller or maximized combination ICS/LABA).
    • Include exacerbation history (eg, ≥2 exacerbations or prior hospitalization in 12 months).
    Step Therapy

    Eucrisa step requirement

    Eucrisa initial approval requires trial and failure (or contraindication/intolerance) to one prescription‑strength topical corticosteroid unless the affected area is sensitive.

    • Document a minimum trial of a prescription topical corticosteroid (or documented contraindication/intolerance).
    Step Therapy

    Conventional therapy trial for RA

    RA initial therapy prior authorization requires documentation of a minimum 3‑month trial and failure/contraindication/intolerance to one conventional DMARD (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses prior to biologic or advanced therapy.

    • Provide treatment dates, doses, and rationale for failure/intolerance for the conventional DMARD trial.
    • Ensure prescriber documentation (rheumatology) is included.
    Step Therapy

    Psoriasis step therapy

    For psoriatic disease and plaque psoriasis, prior authorization requires documented conventional therapy trials of defined durations (e.g., minimum 4‑week topical therapy trial for plaque psoriasis) before biologic approval.

    • Include documentation of the topical/systemic therapy trial, duration (e.g., 4 weeks for topical), and reason for failure/intolerance.
    • Record BSA or other severity metrics per the policy.
    Step Therapy

    Therapeutic trial requirements

    Several products require therapeutic trials or failures of specified alternative agents (for example, acute migraine dihydroergotamine requires prior trial/failure or contraindication to a triptan).

    • Provide documentation of prior class‑specific trials (e.g., triptan trial for acute migraine agents).
    • If contraindication, include clinical notes explaining rationale.
    Step Therapy

    ACE/ARB and SGLT2 step requirements

    Kerendia (for CKD with T2D) requires a minimum 30‑day trial of a maximally tolerated ACE inhibitor or ARB (unless contraindicated) and either concomitant SGLT2 inhibitor use or documentation of SGLT2 contraindication/intolerance.

    • Document at least a 30‑day trial of ACE inhibitor or ARB at maximally tolerated dose, or document contraindication/intolerance.
    • Show SGLT2 inhibitor use and plan to continue, or document contraindication/intolerance to SGLT2 agents.
    Step Therapy

    Step or prior therapy requirements (selected)

    Multiple products require prior trial and failure of specified agents before approval (examples: dihydroergotamine requires prior triptan trial; Lumakras requires prior systemic therapy and documented KRAS G12C mutation).

    • Attach evidence of required prior systemic therapy trials where specified.
    • Include molecular testing reports when targeted agents require mutation confirmation.
    Step Therapy

    Step/step-up therapy

    Many entries require trial and failure, contraindication, or intolerance to specified alternative agents (e.g., droxidopa requires trial of fludrocortisone or midodrine; Nucala/Nucala‑class agents require controller therapy trials and eosinophil counts).

    • Document prior agent trials and outcomes (dates, doses, reasons for discontinuation).
    • Include baseline lab values where required (e.g., eosinophil counts for eosinophilic indications).
    Step Therapy

    Required trials before specialty drugs

    Specialty and high‑cost products routinely require prior trial and failure (TF), contraindication, or intolerance to specified agents (for example, antipsychotic trials for antipsychotics; DMARDs for RA) before authorization.

    • Confirm and document the full history of standard therapy trials per the product's required sequence.
    • Provide specialist consultation notes for complex indications.
    Step Therapy

    Step therapy for infliximab

    Infliximab initial authorization generally requires documentation of moderate‑to‑severe disease activity and prior trial/failure/contraindication/intolerance to specified conventional therapies (e.g., azathioprine, methotrexate, corticosteroids).

    • Provide objective disease activity measures (CDAI>220, stool frequency, CRP, weight loss, endoscopy findings) as applicable.
    • Document trials and outcomes of conventional immunomodulators or corticosteroids.
    Step Therapy

    Step therapy for FN prophylaxis

    Rolvedon for febrile neutropenia prophylaxis requires prior trial and failure or intolerance to specified pegfilgrastim/filgrastim biosimilars (Neulasta, Udenyca) before approval.

    • Document prior use and inadequate response or intolerance to Neulasta/Neulasta Onpro or Udenyca/Udenyca Onbody.
    • Include oncology/chemotherapy plan and FN risk justification.
    Step Therapy

    Required prior therapy trials (dermatology/neurology examples)

    Many dermatology and neurology agents require documented failure, contraindication, or intolerance to specified prior therapies (e.g., two anticonvulsants prior to certain adjunctive therapies; topical therapy trial before psoriasis biologics).

    • Provide clear documentation of prior systemic or topical therapy trials with duration and reasons for failure.
    • When policy requires two prior agents, include both trial records.
    Step Therapy

    Referenced trial/failure requirements (oncology example)

    Some oncology entries and targeted therapies reference required trial/failure of other therapies or specific combinations (e.g., erlotinib combinations); include prior systemic therapy history and molecular testing where applicable.

    • Document prior systemic therapy lines and combination regimens.
    • Attach molecular testing reports when targeted agents require specific mutations/rearrangements.
    Documentation Required

    Required clinical documentation (general)

    Providers must submit required clinical documentation with prior authorization requests: diagnosis confirmation, evidence of prior therapy trials (dates/doses/outcomes), and disease‑specific objective measures; reauthorization requires evidence of positive clinical response.

    • Include chart notes, lab results, imaging, scores (e.g., BSA, CDAI, ALSFRS‑R) that directly support the diagnosis and response.
    • When molecular tests are required, attach FDA‑approved or CLIA‑certified test reports.
    Documentation Required

    Diabetes diagnostic documentation

    For diabetes therapies (e.g., GLP‑1, tirzepatide), submit medical records confirming T2DM diagnosis or qualifying laboratory evidence (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour OGTT ≥200 mg/dL).

    • Attach recent lab results meeting the diagnostic thresholds if chart notes are not sufficient.
    • Specify the indication (T2DM vs MASH) and include relevant specialty consult when required.
    Documentation Required

    Benlysta required documentation

    Benlysta (SLE) prior authorization requires documentation of active SLE, positive serology (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL), and current standard‑of‑care treatment.

    • Include ANA or anti‑dsDNA lab results meeting the specified thresholds.
    • Document current use of standard‑of‑care therapy (antimalarials, corticosteroids, immunosuppressants).
    Documentation Required

    Cystic fibrosis required information

    For cystic fibrosis products (e.g., Cayston), prior authorization must include confirmation of CF diagnosis and microbiologic evidence of Pseudomonas aeruginosa in the lungs.

    • Provide culture or other microbiologic documentation confirming Pseudomonas aeruginosa.
    • Include CF diagnostic evidence and specialist involvement (CF center/pulmonologist).
    Documentation Required

    Cholbam — diagnostic documentation

    Cholbam (chenodeoxycholic acid) requires diagnostic documentation of bile acid synthesis disorders by abnormal urinary bile acid analysis by mass spectrometry or molecular genetic testing; peroxisomal disorders require genetic testing or abnormal bile acid analysis plus clinical features.

    • Attach mass spectrometry urinary bile acid analysis or molecular genetic test reports.
    • Document related clinical features (e.g., liver disease, steatorrhea, fat‑soluble vitamin complications) for peroxisomal disorders.
    Documentation Required

    Deferasirox — baseline labs and transfusion history

    Deferasirox prior authorization for transfusional iron overload must include baseline ferritin >1,000 mcg/L and transfusion history of at least 100 mL/kg packed RBCs; NTDT entries require LIC thresholds per policy.

    • Attach baseline ferritin >1,000 mcg/L lab result and documentation of cumulative transfusion volume (≥100 mL/kg).
    • For NTDT, include LIC measurement (≥5 mg Fe/g dw initial) and serum ferritin per criteria.
    Documentation Required

    Metyrosine diagnostic documentation

    Metyrosine preoperative use requires biochemical confirmation of pheochromocytoma (plasma free metanephrines or urinary fractionated metanephrines) and documentation that the medication is intended for preoperative preparation.

    • Attach plasma free or urinary fractionated metanephrines supporting the diagnosis.
    • Document the planned surgical procedure and preoperative use rationale.
    Documentation Required

    Dupilumab EoE documentation

    Dupilumab for eosinophilic esophagitis requires documentation of ≥15 intraepithelial eosinophils per high power field, exclusion of other causes of esophageal eosinophilia, weight ≥15 kg, and prior trial of PPI or topical esophageal corticosteroid.

    • Include pathology report documenting ≥15 eos/hpf.
    • Provide evidence of prior 8‑week PPI trial or topical steroid trial and exclusion of alternative causes.
    Documentation Required

    Evrysdi required baseline documentation

    Evrysdi prior authorization requires baseline motor function testing (HINE‑2, HFMSE, RULM, CHOP‑INTEND, MFM‑32, or BSID‑III Item 22) and genetic confirmation (SMN1 mutation/deletion and SMN2 copy number) before approval.

    • Attach genetic testing (SMN1/SMN2) and baseline motor exam results appropriate to age.
    • Document whether prior gene therapy was administered and rationale if combined therapies are considered.
    Documentation Required

    Fabrazyme diagnostic documentation

    Fabrazyme prior authorization must include molecular genetic testing demonstrating pathogenic GLA mutation or α‑Gal A enzyme deficiency testing (plasma, leukocytes, or DBS) or documentation of significant clinical manifestations consistent with Fabry disease.

    • Provide GLA genetic test report or enzyme activity testing results.
    • Include clinical documentation of Fabry manifestations when genetic/enzymatic testing is not the primary evidence.
    Documentation Required

    Required medical documentation (general)

    For prior authorization, submit medical records (chart notes, labs, imaging) documenting diagnoses, confirmatory testing (e.g., C1‑INH antigenic/functional levels for HAE; FDA‑approved or CLIA‑approved molecular tests for tumor markers), prior therapy history, and clinical response evidence for reauthorization.

    • Include copies of specialist notes, lab/imaging reports, and detailed prior therapy timelines.
    • For molecularly targeted agents attach the FDA‑approved/CLIA test report used to confirm mutation/rearrangement.
    Documentation Required

    Pediatric growth documentation

    Growth‑hormone related products require documentation of growth measurements, bone age, genetic testing when indicated, GH stimulation test results, and IGF‑1 monitoring as specified.

    • Attach height/weight growth charts, bone age radiograph, and GH stimulation test results when required.
    • Include genetics testing if the indication (e.g., SHOX deficiency) specifies it.
    Documentation Required

    Genomic test documentation

    For targeted oncology agents, include documentation of the tumor type and presence of specific actionable mutations/rearrangements detected by an FDA‑approved or CLIA‑certified test (e.g., KRAS G12C for Lumakras, RET fusion for Retevmo) and prior systemic therapy history when required.

    • Attach molecular test report (FDA‑approved or CLIA) confirming the actionable mutation.
    • Document prior systemic therapy lines and combination regimen details where policy requires prior therapy.
    Documentation Required

    CFTR mutation testing

    CFTR mutation testing must be submitted for cystic fibrosis therapies requiring a responsive CFTR mutation (e.g., ivacaftor/Kalydeco); include the FDA‑cleared or CLIA‑approved test report showing the eligible mutation.

    • Provide the specific CFTR mutation test results demonstrating a mutation responsive to the requested CFTR modulator.
    • Include CF diagnostic confirmation and specialist prescriber notes.
    Documentation Required

    Lumakras required documentation

    For Lumakras requests, include documentation of tumor type and stage, and confirm presence of KRAS G12C mutation by an FDA‑approved or CLIA‑authorized test; also provide prior therapy history consistent with the indication.

    • Attach KRAS G12C test report (FDA‑approved or CLIA).
    • Document prior systemic therapy exposures (e.g., one or more prior lines for NSCLC; prior fluoropyrimidine/oxaliplatin/irinotecan for mCRC).
    Documentation Required

    Mavyret documentation

    Mavyret prior authorization requires documentation consistent with current AASLD/IDSA guidance: HCV diagnosis or donor‑derived infection, absence of decompensated liver disease (Child‑Pugh B/C excluded), and not used with other HCV DAAs; specialist involvement is required for some patients.

    • Provide HCV diagnosis evidence per guideline or transplant donor history.
    • Document Child‑Pugh class to exclude decompensated liver disease when applicable.
    Documentation Required

    Dihydroergotamine documentation

    For dihydroergotamine authorization, document the migraine diagnosis and prior trial and failure (or contraindication) to at least one triptan.

    • Attach migraine history and documentation of a triptan trial (dates, agent, outcome) or note contraindication to triptans.
    Documentation Required

    Posaconazole documentation

    Posaconazole prophylaxis requires documentation of indication (HSCT with GVHD or hematologic malignancy with prolonged neutropenia or prior fungal infection), age ≥13 for prophylaxis/OPC when specified, and trial/failure or resistance to fluconazole for OPC.

    • Provide indication justification (HSCT with GVHD, prolonged neutropenia, or prior fungal infection).
    • For OPC, include fluconazole trial failure or susceptibility report showing resistance.
    Documentation Required

    Ofev documentation

    Ofev (nintedanib) prior authorization requires documentation excluding other ILD causes and HRCT or biopsy demonstrating IPF/SSc‑ILD or chronic fibrosing ILD with ≥10% fibrotic features and evidence of a progressive phenotype when applicable.

    • Attach HRCT report demonstrating UIP/probable IPF or ≥10% fibrotic lung volume for chronic fibrosing ILD.
    • Include clinical evidence of progression (decline in FVC, worsening symptoms, radiologic progression).
    Documentation Required

    Ozempic — required documentation

    Ozempic prior authorization requires medical records confirming T2DM diagnosis or qualifying lab values (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour OGTT ≥200 mg/dL); for MASH include noninvasive scoring (FAST/MAST) or liver biopsy with fibrosis stage F2‑F3.

    • Provide diabetes lab evidence or chart documentation for T2DM.
    • For MASH, attach FAST/MAST results or liver biopsy staging showing F2‑F3 fibrosis.
    Documentation Required

    Piqray — required diagnostic testing

    Piqray prior authorization requires documentation of PIK3CA mutation by an FDA‑approved or CLIA‑approved test and prior endocrine therapy for advanced/metastatic breast cancer.

    • Attach PIK3CA mutation test report from an FDA‑approved or CLIA lab.
    • Document prior endocrine therapy history and disease setting (advanced/metastatic).
    Documentation Required

    ALS diagnostic documentation

    Edaravone prior authorization requires submission of medical records and diagnostic testing supporting definite or probable ALS per the revised El Escorial criteria, ALSFRS‑R item scores ≥2, and %FVC ≥80% at treatment start.

    • Attach documentation supporting ALS diagnosis per revised El Escorial criteria.
    • Include baseline ALSFRS‑R item scores and percent FVC values meeting the policy thresholds.
    Documentation Required

    Anemia laboratory documentation

    For anemia indications (e.g., ESAs, Retacrit), include hemoglobin/hematocrit lab values within specified timeframes to support severity (CKD: within 30 days; chemotherapy: within 2 weeks) and verify iron status where required.

    • Provide Hgb/Hct labs drawn within the timeframe required by the indication.
    • Include iron studies and other workup to rule out alternative causes when specified.
    Documentation Required

    Molecular test documentation

    Targeted therapies require documentation of tumor molecular testing (FDA‑approved or CLIA‑certified) appropriate to the agent (e.g., RET fusion for Retevmo); include the test report with the PA request.

    • Attach the molecular pathology/genomic test report showing the actionable alteration.
    • Ensure the testing method meets FDA or CLIA requirements as specified.
    Documentation Required

    Diagnostic and renal function documentation (Rivfloza)

    Rivfloza initial authorization requires documentation confirming PH1 via elevated urinary or plasma oxalate plus genetic testing demonstrating AGXT mutation or liver biopsy showing reduced/absent AGT activity, and preserved renal function (eGFR ≥30 mL/min/1.73 m2).

    • Provide urinary/plasma oxalate results and AGXT genetic testing or liver biopsy report.
    • Include eGFR demonstrating ≥30 mL/min/1.73 m2.
    Documentation Required

    Required diagnostic documentation (selected)

    Required diagnostic documentation varies by product and indication; always include diagnosis confirmation, relevant lab values (A1c, LDL, eosinophils, platelet counts), and specialty prescriber notes when requested by the policy.

    • Match submitted documentation to the exact 'Required Medical Information' fields in the product entry.
    • For reauthorization include documented positive clinical response as defined by the product.
    Documentation Required

    Immune globulin documentation

    Immune globulin (IV/SC) prior authorization requires documentation showing the minimum effective dose/frequency, route (subcutaneous vs intravenous), the supporting diagnosis (e.g., CIDP or specified primary immunodeficiencies), and relevant immunologic evaluation (IgG levels and vaccine response when applicable).

    • Provide IgG levels, vaccine response testing, and diagnosis supporting SCIG/IVIG use.
    • Document dosing plan and rationale for minimum effective dose for maintenance.
    Documentation Required

    GI agents — required clinical information

    For Crohn's disease or ulcerative colitis biologic induction (IV), prior authorization requires documentation of diagnosis and objective disease activity measures (e.g., CDAI >220 for CD; stool frequency, ulcers, CRP for UC) and weight for FDA‑labeled induction dosing.

    • Include CDAI score or equivalent objective disease activity measures for CD.
    • Provide patient weight to support weight‑based IV induction dosing per label (≤55 kg, >55–85 kg, >85 kg).
    Documentation Required

    Tegsedi documentation

    Tegsedi (inotersen) requires documentation of hATTR with polyneuropathy, a pathogenic TTR mutation, and baseline neuropathy scores within specified ranges (PND ≤ IIIb, FAP stage 1–2, or NIS 10–130); prescriber should be a neurologist and reauthorization requires demonstrated clinical response.

    • Attach TTR genetic test results and baseline neuropathy assessments (PND, FAP stage, or NIS).
    • Include neurologist consultation notes and response evidence for reauth.
    Denial Risk

    Missing required diagnosis or prior therapy

    Failure to include the required diagnosis or documentation of prior therapy trials (where specified) will likely result in denial of coverage (examples: missing diagnosis for Actimmune; missing prior TF/C/I for therapies requiring such trials).

    • Verify that the submitted diagnosis exactly matches the policy's required diagnosis.
    • Ensure all required prior therapy trials and their durations/outcomes are documented.
    Denial Risk

    Missing required diagnostic evidence

    Coverage may be denied if required diagnostic evidence is not provided (e.g., for Benlysta, absence of ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL and current standard‑of‑care treatment documentation).

    • Confirm autoantibody lab results meet the specified thresholds and include current SOC therapy documentation.
    • If labs are missing, attach recent lab reports or explain why testing cannot be obtained.
    Denial Risk

    Missing microbiologic evidence

    Requests for CF therapies like Cayston may be denied if microbiologic evidence of Pseudomonas aeruginosa in the lungs is not provided; include culture or other microbiologic documentation with the PA.

    • Include sputum or respiratory culture confirming Pseudomonas aeruginosa.
    • If culture not available, provide clinical justification and prior microbiologic history.
    Denial Risk

    Pyrimethamine — malaria not authorized

    Requests for pyrimethamine products for malaria treatment or prophylaxis are not authorized and will be denied per policy; pyrimethamine use is limited to toxoplasmosis indications as specified.

    • Do not submit PA requests for pyrimethamine for malaria treatment or prophylaxis—these uses are excluded.
    • For toxoplasmosis, ensure infectious disease specialist documentation is provided.
    Denial Risk

    Deferasirox documentation risk

    Deferasirox requests lacking documentation of baseline ferritin >1,000 mcg/L and cumulative transfusion history (≥100 mL/kg packed RBCs) for transfusional iron overload will risk denial.

    • Provide baseline ferritin >1,000 mcg/L laboratory report and transfusion records totaling ≥100 mL/kg.
    • For NTDT include LIC measurements per policy thresholds.
    Denial Risk

    Enbrel prior therapy requirement

    Enbrel requests may be denied if the required prior conventional DMARD trial (e.g., methotrexate, leflunomide, sulfasalazine) of adequate duration (commonly 3 months for RA) is not documented.

    • Include documentation of the conventional DMARD trial with duration and reason for failure/intolerance.
    • Attach rheumatology consultation notes when applicable.
    Denial Risk

    ALK-inhibitor naïve requirement (lorlatinib example)

    ALK‑inhibitor therapies (e.g., lorlatinib) will be denied if the patient previously received an ALK inhibitor; initial approval requires ALK‑inhibitor naïve status and confirmed ALK rearrangement.

    • Confirm absence of prior ALK inhibitor exposure for initial authorization.
    • Attach ALK rearrangement test report (FDA‑approved or CLIA).
    Denial Risk

    Combination prophylaxis exclusion

    HAE prophylaxis agents (Cinryze, Haegarda) used in combination with other approved prophylactic HAE treatments are not permitted and such combination requests may be denied.

    • Do not request concurrent prophylactic HAE agents in the same patient for the same prophylactic purpose.
    • If combination therapy was used, provide justification and note policy exclusion.
    Denial Risk

    Required trials for autoimmune indications

    Failure to document required prior trials (including minimum durations) of specified conventional therapies for autoimmune indications (RA, PJIA, PsO, AS, etc.) may result in denial.

    • Ensure prior conventional therapy trials meet the policy's minimum duration (e.g., 3 months for RA, 4 weeks topical for psoriasis, 1 month NSAID for AS).
    • Provide documentation of failure, intolerance, or contraindication.
    Denial Risk

    IVIG renewal requirement

    IVIG non‑oncology reauthorization requires documentation of objective improvement and that therapy is at the minimum effective dose; failure to show these will risk denial.

    • Provide objective clinical improvement measures and document dosing adjustments towards minimum effective dose for maintenance.
    • Attach specialist evaluation supporting continued IVIG use.
    Denial Risk

    Documentation and prior therapy gaps

    Requests missing required diagnosis, prior therapy trials, or documentation of intolerance/contraindication to listed alternatives are at high risk for denial.

    • Review each product's 'Required Medical Information' and ensure all fields are completed and supported by records.
    • If prior therapy cannot be documented, include clinician explanation and supporting evidence.
    Denial Risk

    Dihydroergotamine initial therapy

    Dihydroergotamine initial therapy will be denied if the requester does not document prior trial and failure of a triptan (or documented contraindication to all triptans).

    • Include records of triptan trial and outcome, or clear documentation of contraindication to triptans.
    Denial Risk

    Lumakras molecular test and prior therapy

    Lumakras requests for NSCLC or mCRC without documentation of KRAS G12C mutation (FDA‑approved or CLIA‑authorized test) or required prior therapy history will be denied.

    • Attach KRAS G12C molecular test report and prior systemic therapy documentation (as required by indication).
    Documentation Required

    Neulasta prophylaxis documentation

    Neulasta prophylaxis requests must include documentation of the chemotherapy regimen's FN risk or prior FN history; missing this documentation may lead to denial.

    • Provide chemotherapy regimen details and FN risk justification, or documentation of prior FN event if used as secondary prophylaxis.
    Denial Risk

    Diagnosis and disease status documentation

    Requests lacking a documented diagnosis matching the policy's required medical information (e.g., specific cancer type or disease stage) or evidence of refractory/progressive disease may be denied.

    • Ensure the submitted diagnosis and staging exactly match the product's Required Medical Information.
    • Provide progression evidence or rationale when indicated.
    Denial Risk

    Prior therapy requirement for droxidopa

    Droxidopa requires prior authorization documenting failure/contraindication/intolerance to fludrocortisone or midodrine; absence of that documentation may result in denial.

    • Provide trial records for fludrocortisone and/or midodrine including duration and reason for failure/intolerance.
    • Include specialist consultation notes as required.
    Denial Risk

    Eosinophil and prior therapy documentation

    For eosinophilic/Type 2 condition biologics (e.g., Nucala, Fasenra), missing baseline eosinophil counts, prior exacerbation history, or documentation of required prior controller therapy may lead to denial.

    • Attach baseline eosinophil lab result and exacerbation/hospitalization history in past 12 months.
    • Include prior controller therapy documentation (ICS dose and additional controllers) per age group.
    Denial Risk

    Orencia — RA/PJIA/PsA initial requirements

    Orencia initial requests for RA, PJIA, or PsA may be denied if the diagnosis or required prior trial/failure of specified conventional therapies (with minimum durations) is not documented.

    • Provide documentation of TF/C/I to methotrexate, leflunomide, or sulfasalazine with the specified minimum trial durations.
    • Include rheumatology prescriber or consult notes.
    Denial Risk

    Opsumit/Orenitram — PAH diagnostic confirmation

    PAH therapy requests (Opsumit/Orenitram) lacking documentation of diagnosis confirmed by right heart catheterization or evidence the patient is currently on PAH therapy may be denied; prescriber should be a pulmonologist or cardiologist.

    • Attach right heart catheterization report or documentation of current PAH therapy.
    • Include pulmonology/cardiology prescriber notes or consultation.
    Denial Risk

    Documentation for PCSK9 (Praluent)

    Praluent requests missing documentation of the qualifying diagnosis (HeFH/ASCVD/Primary HLD/HoFH) or failure/intolerance to maximally tolerated statin therapy and other lipid‑lowering regimens will be denied.

    • Provide LDL labs on maximally tolerated therapy and documentation of statin intolerance or contraindication where claimed.
    • For HoFH include genetic confirmation or the LDL/xanthoma family history criteria.
    Denial Risk

    Documentation for Eltrombopag

    Eltrombopag requests without required baseline platelet counts (e.g., <30,000/mcL for ITP) or without documentation of prior corticosteroid/IVIG/splenectomy trials may be denied.

    • Attach baseline platelet count demonstrating policy threshold.
    • Provide prior therapy trial records (corticosteroids, IVIG, splenectomy) with outcomes.
    Denial Risk

    Documentation for Infliximab

    Infliximab requests missing objective diagnostic support of moderate‑to‑severe disease activity or documentation of failure/intolerance to required conventional therapies (e.g., azathioprine, methotrexate, corticosteroids) may be denied.

    • Include CDAI, stool frequency, CRP, endoscopy, or other objective disease activity measures for IBD indications.
    • Document prior immunomodulator or steroid trials and outcomes for rheumatologic/IBD indications.
    Denial Risk

    Missing required medical information

    Requests may be denied if required diagnostic labs or documentation (e.g., hemoglobin/hematocrit values for anemia indications) are not provided within the policy‑specified timeframes.

    • Ensure labs are recent within the policy's timeframe (CKD anemia within 30 days; chemo‑related anemia within 2 weeks).
    • Attach all supporting lab reports to the PA submission.
    Denial Risk

    Documentation and prior trial risks

    Failure to document required prior trials (including minimum durations) and prescriber consultation where required (e.g., topical therapy trial for plaque psoriasis) can result in denial for initial coverage.

    • Confirm prior topical/systemic therapy trials and durations meet policy thresholds.
    • Include dermatologist or relevant specialist consult notes when required.
    Denial Risk

    GI biologic induction requirements

    GI biologic induction (IV) requests for Crohn's or UC lacking required diagnosis or objective disease activity measures (e.g., CDAI >220 for Crohn's; >6 stools/day or steroid‑dependent disease for UC) may be denied.

    • Provide CDAI score, stool frequency, ulceration evidence, CRP/ESR, and weight loss where applicable.
    • Include gastroenterologist consultation and planned IV induction dosing per weight.
    Denial Risk

    Tavneos diagnostic and concomitant therapy requirements

    Tavneos prior authorization requires documentation of ANCA‑associated vasculitis subtype (GPA or MPA), positive ANCA or biopsy confirmation, and concurrent immunosuppressant therapy (cyclophosphamide or rituximab) plus glucocorticoid use or documented contraindication; absence of these will risk denial.

    • Attach ANCA (PR3 or MPO) positive test or tissue biopsy report confirming GPA/MPA.
    • Document concurrent use of cyclophosphamide or rituximab and glucocorticoid therapy or intolerance to glucocorticoids.
    Note

    Policy Background and Scope

    This excerpt summarizes indication‑specific coverage requirements for multiple specialty medications used in immunology and related areas. It emphasizes that approval depends on a documented diagnosis, required diagnostic testing or laboratory thresholds when specified, appropriate prior therapy trials or documented intolerance/contraindication, and prescriber specialty or consultation when required. Many products have defined initial coverage durations (commonly 6 months for initial approvals of some biologics and specialty agents and 12 months for ongoing therapy) and reauthorization generally requires evidence of clinical benefit.

    Definitions and Key Terms

    inv-305: TF/C/I
    TF/C/I definitionTrial and failure, contraindication, or intolerance — documented trial and lack of benefit or intolerance to specified prior therapies
    UseApplied across multiple indications as prerequisite to specialty therapy approval
    DocumentationMedical records must confirm duration and reason (failure, contraindication, or intolerance)
    inv-306: BSA
    BSA threshold (psoriasis)>= 3% BSA for plaque psoriasis biologics initial criteria; other entries use >=10% BSA for severe AD context
    Context differences>=3% BSA commonly used for plaque psoriasis biologic eligibility; >=10% used for atopic dermatitis severity in some product criteria
    DocumentationBSA involvement must be recorded in clinical notes for prior authorization
    inv-307: Autoantibody positive (SLE)
    Autoantibody positive (SLE)Defined as ANA titer >=1:80 OR anti-dsDNA >=30 IU/mL required for Benlysta coverage
    ApplicationRequired documentation for SLE initial authorization
    PrescriberPrescribed by or in consultation with a rheumatologist
    inv-308: Polycythemia vera confirmation
    PV confirmationPolycythemia vera confirmed by hematologic criteria (eg Hgb/Hct thresholds) plus bone marrow panmyelosis and JAK2 mutation or subnormal EPO, or sustained absolute erythrocytosis with JAK2 mutation
    ExamplesHgb >16.5 g/dL (men) or >16.0 g/dL (women); Hct >49% (men) or >48% (women) as part of diagnostic pathways
    CoverageHigh-risk PV pathways include trial and inadequate response documentation; coverage duration 12 months
    inv-309: Reauth positive response
    Reauth positive responseReauthorization of IVIG/SCIG requires objective clinical improvement and therapy at minimum effective dose
    DocumentationMedical records must show improvement in disease-specific measures and dosing optimization
    PrescriberPrescribed by or in consultation with specialist experienced in immune globulin therapy
    inv-310: Eosinophilic phenotype (asthma)
    Eosinophilic phenotype (asthma)Defined as baseline peripheral blood eosinophils >=150 cells/mcL (or >=300 cells/mcL within past 12 months); plus exacerbation history as specified
    Clinical criteriaTwo or more exacerbations requiring systemic steroids in past 12 months OR prior asthma-related hospitalization
    PrescriberPrescribed by or in consultation with pulmonologist or allergist/immunologist
    inv-311: Transfusional hemosiderosis
    Transfusional hemosiderosis criteriaBaseline ferritin >1,000 mcg/L AND transfusion history of at least 100 mL/kg packed RBCs for deferasirox initial approval
    Age minimumIndication applies in patients aged 2 years or older for transfusion-related iron overload
    ReauthReauth requires reduction in ferritin or LIC per product specifics
    inv-312: Baseline motor function exams (SMA)
    Baseline motor exams (SMA)Baseline motor function testing (HINE-2, HFMSE, RULM, CHOP-INTEND, MFM-32, or BSID-III Item 22) required prior to SMA therapy initiation
    Genetic confirmationSMN1 homozygous deletion or compound heterozygous mutation and SMN2 copy number documented
    Concomitant therapyNo concomitant chronic SMN-modifying therapy unless prior gene therapy failure documented
    inv-313: HAE diagnostic confirmation
    HAE diagnostic confirmationDiagnosis confirmed by low C1-INH antigenic level OR low C1-INH functional level (Type I or II)
    ApplicationRequired for both acute treatment and prophylaxis entries (eg Icatibant, Cinryze, Haegarda)
    PrescriberPrescribed by or in consultation with immunologist or allergist per product notes
    inv-315: Molecularly defined oncology indications
    Molecularly defined oncology indicationsTumor-specific gene fusions or activating mutations must be detected by FDA-approved or CLIA-approved tests (eg RET fusion, BRAF V600E/K, FGFR2, EGFR) to support targeted therapy coverage
    DocumentationSubmit molecular test results from FDA-approved or CLIA-certified laboratories
    Coverage durationTypically 12 months with approvals for continuation of prior therapy
    inv-316: IVIG/SCIG
    IVIG/SCIG requirementIVIG must be administered at the minimum effective dose and appropriate frequency for the diagnosis; SCIG reserved for specified primary immunodeficiencies
    Specialist involvementPrescribed by or in consultation with physician experienced in immune globulin therapy (eg immunologist, hematologist, neurologist)
    ReauthNon-oncology renewal requires objective improvement and dose optimization
    inv-317: CLIA/FDA-approved test
    CLIA/FDA-approved test requirementGenetic or biomarker status must be documented by an FDA-approved or CLIA-certified test for targeted therapy eligibility
    ExamplesEGFR, RET, ROS1, BRAF, FGFR2, KRAS, PIK3CA testing cited across oncology entries
    DocumentationProvide lab/test report in prior authorization submission
    inv-318: NOMID
    NOMID confirmationNOMID diagnosis confirmed by NLRP3 gene mutation OR clinical criteria plus elevated acute phase reactants
    PrescriberPrescribed by or in consultation with appropriate specialist (eg pediatric rheumatologist) per entry
    ReauthReauth requires evidence of positive clinical response
    inv-319: Livmarli indications (ALGS and PFIC)
    Livmarli indicationsALGS: JAG1 or NOTCH2 mutation; PFIC: mutations in ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or MYO5B required by molecular genetic testing
    Age limitsALGS initial: patient >=3 months; PFIC initial: patient >=12 months
    Prior therapyInadequate response to at least one pruritus treatment required prior to approval
    inv-320: BRAF V600E/V600K mutation
    BRAF V600 mutation requirementBRAF V600E or V600K mutation detected by FDA-approved or CLIA test required for BRAF-targeted combinations
    Combination useTherapies used in specified combinations (eg BRAF + MEK) per indication-specific rules
    CoverageTypical 12-month duration; continuation approvals supported
    inv-321: FGFR2 fusion/rearrangement
    FGFR2 fusion/rearrangementPresence of FGFR2 fusion or rearrangement by FDA-approved or CLIA test required for intrahepatic cholangiocarcinoma targeted therapy (eg Lytgobi)
    Prior therapyPrior chemotherapy is typically required per product entry
    CoverageCoverage duration commonly 12 months; continuation allowed
    inv-322: Eosinophilic phenotype (as applied to asthma)
    Eosinophilic phenotype (as applied to asthma)Baseline peripheral blood eosinophils >=150 cells/µL OR >=300 cells/µL within past 12 months, plus history of >=2 exacerbations requiring systemic corticosteroids or prior hospitalization
    Controller therapyRequires prior use of age-appropriate high/medium-dose ICS plus additional controller or maximized ICS/LABA regimens per age band
    PrescriberPrescribed by pulmonologist or allergist/immunologist
    inv-323: Progressive phenotype (chronic fibrosing ILD)
    Progressive phenotype (chronic fibrosing ILD)Requires HRCT showing >=10% lung volume with fibrotic features plus evidence of progression (decline in FVC, worsening symptoms, or radiologic progression)
    PrescriberPrescribed by or in consultation with a pulmonologist
    CoverageInitial and reauth typically 12 months; reauth requires positive clinical response
    inv-324: Reauthorization response requirement
    Reauthorization response requirementContinuation approvals require evidence of positive clinical response (eg reduction in swollen/tender joint count, BSA reduction, mucosal healing, improved labs)
    DocumentationSubmit clinical measures comparing baseline to on-therapy status for reauth
    Typical reauth duration12 months for most products
    inv-325: MASH confirmation
    MASH confirmationMASH diagnosis requires FAST or MAST noninvasive scoring or liver biopsy with fibrosis stage F2–F3
    PrescriberPrescribed by or in consultation with gastroenterologist/hepatologist for MASH indications
    CoverageInitial coverage 12 months; reauth requires positive clinical response
    inv-326: HoFH
    HoFH confirmationHoFH confirmed by genetic confirmation of two pathogenic mutations in LDLR/ApoB/PCSK9/LDLRAP1/ARH OR by LDL thresholds (untreated LDL>400 mg/dL or treated LDL>300 mg/dL) plus early xanthoma or parental HeFH evidence
    Age restrictionInitial HeFH/HoFH eligibility: age >=10 years
    Concurrent therapyPatient should be receiving other lipid-lowering therapy or have documented inability to take them
    inv-327: ITP baseline
    ITP baselineBaseline platelet count <30,000/mcL required for ITP eligibility for thrombopoietin receptor agonists
    Prior therapyTrial and failure/intolerance/contraindication to corticosteroids, IVIG, or splenectomy typically required
    PrescriberPrescribed by or in consultation with hematologist/oncologist
    inv-328: RET gene fusion/mutation
    RET gene fusion/mutationPresence of RET gene fusion or RET mutation detected by FDA-approved or CLIA-certified test required for Retevmo and similar targeted therapies
    IndicationsApplies to NSCLC, MTC, thyroid cancer, and solid tumors with RET alterations
    CoverageTypical coverage duration 12 months; continuation approvals supported
    inv-329: PH1 confirmation
    PH1 confirmationPH1 diagnosis confirmed by elevated urinary or plasma oxalate PLUS AGXT genetic testing or liver biopsy demonstrating absent/reduced AGT activity; eGFR >=30 mL/min/1.73m2 required
    Age limitInitial: patient >=2 years of age for Rivfloza
    PrescriberPrescribed by or in consultation with hepatologist, nephrologist, urologist, geneticist, or PH1 specialist
    inv-330: Plaque psoriasis initial criteria
    Plaque psoriasis initial criteria>=3% BSA involvement OR severe scalp/palmoplantar/facial/genital disease PLUS minimum 4-week TF/C/I to one topical therapy
    PrescriberPrescribed by or in consultation with a dermatologist
    Coverage durationInitial commonly 6 months; reauth 12 months with evidence of response
    inv-331: IV induction dosing for CD/UC (weight-based)
    IV induction weight bandsIV induction dosing weight thresholds: ≤55 kg; >55–85 kg; >85 kg (used to determine labeled induction doses)
    Example dosingTypical FDA-labeled induction example: ≤55 kg: 260 mg; >55–85 kg: 390 mg; >85 kg: 520 mg (administered as one-time IV induction)
    ApplicationApplies to Crohn's disease/UC biologic IV induction per product labeling
    inv-332: CDAI
    CDAI thresholdCDAI > 220 used as threshold to document moderately to severely active Crohn's disease for biologic eligibility
    ContextAlso accept clinical evidence (weight loss, complications, abnormal CRP) per product-specific criteria
    PrescriberRequirement: prescribed by or in consultation with gastroenterologist
    inv-333: EGFR/BRAF/MET testing
    IV induction dosing amounts≤55 kg: 260 mg; >55–85 kg: 390 mg; >85 kg: 520 mg (FDA-labeled induction dosing examples)
    AdministrationAdministered as a one-time IV induction dose per product labeling prior to maintenance dosing
    Use caseApplies to biologic induction for Crohn's disease and ulcerative colitis per policy